Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.955-962, 2014. ,
DOI : 10.1016/S0140-6736(13)62343-0
URL : https://hal.archives-ouvertes.fr/hal-00935589
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLOS ONE, vol.8, issue.11, p.144856, 2015. ,
DOI : 10.1371/journal.pone.0144856.s007
??pid??miologie et facteurs de risque de la maladie veineuse thromboembolique, Revue des Maladies Respiratoires, vol.29, issue.2, pp.254-266, 2012. ,
DOI : 10.1016/j.rmr.2011.12.001
Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations, Thrombosis Research, vol.136, issue.4, pp.763-768, 2015. ,
DOI : 10.1016/j.thromres.2015.08.006
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban, Clinical Research in Cardiology, vol.105, issue.3, pp.399-412, 2013. ,
DOI : 10.1038/ajg.2009.712
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) ??? March 2013, Archives of Cardiovascular Diseases, vol.106, issue.6-7, pp.382-393, 2013. ,
DOI : 10.1016/j.acvd.2013.04.009
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3, pp.453-460, 2012. ,
DOI : 10.1016/j.amjcard.2012.03.049
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis, Blood, vol.124, issue.15, pp.2450-2458, 2014. ,
DOI : 10.1182/blood-2014-07-590323
Oral rivaroxaban for symptomatic venous thromboembolism, New Engl J Med, vol.363, pp.2499-2510, 2010. ,
Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013. ,
DOI : 10.1056/NEJMoa1302507
URL : https://hal.archives-ouvertes.fr/hal-00932477
Efficacy and Safety of Dabigatran Etexilate and Warfarin in ???Real-World??? Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.61, issue.22, pp.2264-2273, 2013. ,
DOI : 10.1016/j.jacc.2013.03.020
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry, Blood, vol.124, issue.6, pp.955-962, 2014. ,
DOI : 10.1182/blood-2014-03-563577
Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study, Fundamental & Clinical Pharmacology, vol.88, issue.1, pp.106-111, 2015. ,
DOI : 10.1016/j.mayocp.2013.03.006
Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France, Journal of Stroke and Cerebrovascular Diseases, vol.23, issue.2, pp.73-83, 2014. ,
DOI : 10.1016/j.jstrokecerebrovasdis.2013.08.022